Asep Medical Holdings Inc. SEPSF
The SEC does not publish structured financial data (XBRL) for Asep Medical Holdings Inc., so there are no statement tables here.
This is common for foreign companies that trade over the counter and for filers that only submit documents.
Its filings are still listed below and on SEC EDGAR.
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| SEC STAFF ACTION | Filing | Sep 10, 2025 | — |
| F-1/A | Filing | Oct 4, 2024 | — |
| F-1/A | Filing | Aug 9, 2024 | — |
| F-1 | Registration statement (foreign issuer) | May 29, 2024 | — |
| DRS/A | Filing | Jan 19, 2024 | — |
| DRS/A | Filing | Dec 12, 2023 | — |
| DRS/A | Filing | Oct 20, 2023 | — |
| DRS | Filing | Jul 3, 2023 | — |
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- SEPSF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Victoria, British Columbia, Canada
- SEC CIK
- 1969766
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.